Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
Provided is a fusion protein comprising IL-2 protein and CD80 protein. A fusion protein containing CD80 fragment, immunoglobulin Fc, and an IL-2 variant can activate immune cells, such as natural killer cells, and at the same time, can control immune cell regulatory activity of regulatory T cells. Therefore, a pharmaceutical composition containing the fusion protein as an active ingredient is very industrially useful in that such pharmaceutical composition can increase immune activity in the body, and thus can be effectively used against infectious diseases as well as cancer.
1. A composition comprising a caged cytokine wherein the caged cytokine is conjugated to a photon decomposing chemical structure, wherein the photon decomposing chemical structure is conjugated through a linking group to a hydrophilic polymer, wherein the cytokine is interleukin-2, interleukin-7, interleukin-12, or interleukin-15, and wherein the photon decomposing chemical structure has a 2-nitrobenzyl group.
2. The method of claim 1 , wherein n and m are each independently 1.
3. The method of claim 1 , wherein the IL-2 protein comprises the amino acid sequence of SEQ ID NO: 10.
4. The method of claim 1 , wherein the IL-2 protein is an IL-2 variant.
5. The method of claim 4 , wherein the IL-2 variant is obtained by substitution of at least one selected from the 38th, 42nd, 45th, 61st, and 72nd amino acids in the amino acid sequence of SEQ ID NO: 10.
6. The method of claim 4 , wherein the IL-2 variant comprises at least one substitution selected from the group consisting of R38A, F42A, Y45A, E61R, and L72G in the amino acid sequence of SEQ ID NO: 10.
7. The method of claim 4 , wherein the IL-2 variant comprises any one selected from the following substitution combinations (a) to (d) in the amino acid sequence of SEQ ID NO: 10:
(a) R38A/F42A
(b) R38A/F42A/Y45A
(c) R38A/F42A/E61R
(d) R38A/F42A/L72G.
8. The method of claim 4 , wherein the IL-2 variant comprises the amino acid sequence of SEQ ID NO: 6, 22, 23, or 24.
9. The method of claim 1 , wherein the CD80 protein comprises the amino acid sequence of SEQ ID NO: 11.
10. The method of claim 1 , wherein the CD80 protein is a CD80 fragment.
11. The method of claim 10 , wherein the CD80 fragment consists of the 35th amino acid to 242nd amino acid in the amino acid sequence of SEQ ID NO: 11.
12. The method of claim 1 , wherein the Fc domain is a wild type or variant.
13. The method of claim 1 , wherein the Fc domain comprises the amino acid sequence of SEQ ID NO: 4.
14. The method of claim 13 , wherein the variant of the Fc domain comprises the amino acid sequence of SEQ ID NO: 12.
15. The method of claim 1 , wherein the linker (1) is a peptide linker consisting of the amino acid sequence of SEQ ID NO: 3.
16. The method of claim 1 , wherein the linker (2) is a peptide linker consisting of the amino acid sequence of SEQ ID NO: 5.
17. The method of claim 1 , wherein the subject is an individual suffering from cancer, wherein the cancer is any one selected from the group consisting of gastric cancer, liver cancer, lung cancer, colorectal cancer, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer, cervical cancer, thyroid cancer, laryngeal cancer, brain tumor, neuroblastoma, retinoblastoma, head and neck cancer, salivary gland cancer, melanoma and lymphoma.
18. The method of claim 17 , wherein the individual is a mammal or a human.
19. The method of claim 1 , further comprising:
administering, to the subject, a compound or natural extract which has antitumor activity.
20. The method of claim 1 , wherein the immune cells comprise NK cells or T cells.